Free tool
FAERS Monitor: Cobenfy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216158 or its brand name (Cobenfy, Trospium Chloride, Xanomeline Tartrate). Reports on generic versions are filed under their own applications.
Reports
2,767
Serious
669
24% of reports
Hospitalization
249
Death reported
29
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea593
- vomiting439
- constipation202
- off label use195
- urinary retention153
- dizziness127
- dyspepsia112
- hyperhidrosis97
- vision blurred92
- drug ineffective84
- dry mouth82
- heart rate increased65
- treatment noncompliance65
- somnolence63
- gastrointestinal disorder62
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 172 |
| 2025 | 1,254 |
| 2026 | 1,341 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| urinary retentionSignal | 153 | 35.0 | 30.0 | 5,007 |
| treatment noncomplianceSignal | 65 | 9.0 | 7.1 | 457 |
| dyspepsiaSignal | 112 | 8.7 | 7.2 | 754 |
| dry mouthSignal | 82 | 7.7 | 6.2 | 472 |
| vomitingSignal | 439 | 7.1 | 6.5 | 2,346 |
| constipationSignal | 202 | 7.0 | 6.2 | 1,052 |
| hyperhidrosisSignal | 97 | 5.7 | 4.7 | 376 |
| nauseaSignal | 593 | 5.7 | 5.3 | 2,381 |
| gastrointestinal disorderSignal | 62 | 5.3 | 4.1 | 211 |
| vision blurredSignal | 92 | 5.1 | 4.2 | 301 |
| heart rate increasedSignal | 65 | 5.0 | 3.9 | 204 |
| somnolenceSignal | 63 | 2.4 | 1.9 | 49 |
| dizziness | 127 | 1.9 | 1.6 | 58 |
| off label use | 195 | 1.7 | 1.5 | 57 |
| drug ineffective | 84 | 0.5 | 0.4 | 49 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.